



SEQUENCE LISTING

<110> Perlan Therapeutics  
Fang, Fang

<120> Identifying Ligands of Target Proteins With Target  
Complementary Library Technology (TCLT)

<130> 014357-0278746

<140> 09/674,014

<141> 2001-02-08

<150> WO PCT/US99/06537

<151> 1999-04-19

<150> US 60/083,046

<151> 1998-04-24

<160> 27

<170> PatentIn Ver. 2.0

<210> 1

<211> 15

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sense strand of  
target gene

<400> 1

cuuuguuucu uuuuu

15

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sense strand of  
target gene encoded peptide

<400> 2

Leu Val Leu Phe

1

*Bea'id.*

<210> 3  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: anti-sense  
peptide encoded by anti-sense strand

<400> 3

Lys Lys Asn Lys  
1

<210> 4  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: anti-sense  
strand

<400> 4

aaaaagaaca ag

12

<210> 5  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: anti-sense  
peptide encoded by anti-sense strand

<400> 5

Glu Gln Glu Lys  
1

<210> 6  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: anti-sense  
strand

<400> 6

gaacaagaaa aa

12

<210> 7  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
degenerate BglI deoxyoligonucleotide fragment

<220>  
<221> modified\_base  
<222> (1)..(20)  
<223> phosphoramidite nucleotides

<400> 7

ctgtcagggc ccgaggggct

20

<210> 8  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
degenerate BglI deoxyoligonucleotide fragment

<220>  
<221> modified\_base  
<222> (1)..(22)  
<223> phosphoramidite nucleotides

<400> 8

ggggccgctg cggcctgtca gg

22

<210> 9  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ICAM-1 domain  
D1 residues 1-5 peptide target for human  
rhinovirus (HRV)

<400> 9

Gln Thr Ser Val Ser  
1 5

<210> 10  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ICAM-1 domain  
D1 residues 24-29 peptide target for human  
rhinovirus (HRV)

<400> 10

Ser Cys Asp Gln Pro Lys  
1 5

<210> 11  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ICAM-1 domain  
D1 residues 40-49 peptide target for human  
rhinovirus (HRV)

<400> 11

Lys Glu Leu Leu Leu Pro Gly Asn Asn Arg  
1 5 10

β  
<210> 12  
<211> 8  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence: ICAM-1 domain  
D1 residues 70-77 peptide target for human  
rhinovirus (HRV)

<400> 12

Pro Asp Gly Gln Ser Thr Ala Lys  
1 5

<210> 13  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: general  
sequence of framework 2 (FR2) region from V-H1  
family heavy chain

<220>  
<221> MOD\_RES  
<222> (3)

<223> Xaa = Arg or Gln

<220>

<221> MOD\_RES

<222> (6)

<223> Xaa = Pro, His or Thr

<220>

<221> MOD\_RES

<222> (7)

<223> Xaa = Gly or Ala

<220>

<221> MOD\_RES

<222> (8)

<223> Xaa = Lys or Gln

<220>

<221> MOD\_RES

<222> (9)

<223> Xaa = Gly, Glu, Arg or Ala

<220>

<221> MOD\_RES

<222> (11)

<223> Xaa = Glu or Gly

<220>

<221> MOD\_RES

<222> (13)

<223> Xaa = Met or Ile

<400> 13

Trp Val Xaa Gln Ala Xaa Xaa Xaa Xaa Leu Xaa Trp Xaa Gly

1

5

10

<210> 14  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: general  
sequence of framework 2 (FR2) region from V-H2  
family heavy chain

<400> 14

Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala  
1 5 10

<210> 15  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: general  
sequence of framework 2 (FR2) region from V-H3  
family heavy chain

<220>  
<221> MOD\_RES  
<222> (2)  
<223> Xaa = Val or Ile

<220>  
<221> MOD\_RES  
<222> (3)  
<223> Xaa = Arg or His

<220>  
<221> MOD\_RES  
<222> (6)  
<223> Xaa = Pro or Gln

<220>  
<221> MOD\_RES  
<222> (10)  
<223> Xaa = Leu or Pro

<220>  
<221> MOD\_RES  
<222> (11)  
<223> Xaa = Glu or Val

<220>  
<221> MOD\_RES  
<222> (12)  
<223> Xaa = Trp, Tyr or Leu

<220>  
<221> MOD\_RES  
<222> (14)  
<223> Xaa = Ser, Ala or Gly

<400> 15

Trp Xaa Xaa Gln Ala Xaa Gly Lys Gly Xaa Xaa Xaa Val Xaa  
1 5 10

<210> 16

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: general  
sequence of framework 2 (FR2) region from V-H4  
family heavy chain

<220>

<221> MOD\_RES

<222> (2)

<223> Xaa = Ile or Val

<400> 16

Trp Xaa Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly  
1 5 10

<210> 17

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: general  
sequence of framework 2 (FR2) region from V-H5  
family heavy chain

<220>

<221> MOD\_RES

<222> (9)

<223> Xaa = Gly or Glu

<400> 17

Trp Val Arg Gln Met Pro Gly Lys Xaa Leu Glu Trp Met Gly  
1 5 10

<210> 18  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: general  
sequence of framework 2 (FR2) region from V-H6  
family heavy chain

<400> 18

Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly  
1 5 10

<210> 19  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: framework 2  
(FR2) region from V-L kappa light chain

B  
<220>  
<221> MOD\_RES  
<222> (8)  
<223> Xaa = Gln or Lys

<220>  
<221> MOD\_RES  
<222> (9)  
<223> Xaa = Pro, Ser or Ala

<400> 19

Trp Tyr Gln Gln Lys Pro Gly Xaa Xaa Pro Lys Leu Leu Ile Tyr  
1 5 10 15

<210> 20  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: IgE-blocking  
peptide 1 binds to FR2 in V-H5

<220>  
<221> MOD\_RES  
<222> (10)  
<223> Xaa = Gln or Asp

<400> 20

Pro Asp Ala Leu His Gly Pro Phe Ala Xaa Leu Pro His Pro  
1 5 10



<210> 21  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: IgE-blocking  
peptide 2 binds to FR2 in V-H3, V-H4 and V-H6

<220>  
<221> MOD\_RES  
<222> (5)  
<223> Xaa = Gly or Arg

<220>  
<221> MOD\_RES  
<222> (10)  
<223> Xaa = Gln or Asp

<400> 21

Pro Asp Ala Leu Xaa Gly Pro Phe Ala Xaa Leu Pro Asn Pro  
1 5 10

<210> 22  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: IgE-blocking  
peptide 3 binds to FR2 in V-L kappa

<400> 22

Pro Val Leu Leu Phe Arg Pro Leu Arg Gly Phe Glu Glu Asp Ile  
1 5 10 15

<210> 23  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer No.1

<220>  
<221> modified\_base  
<222> (10)..(15)  
<223> n = a, t, c or g

<400> 23

gacgtggccn nnnnn

15

<210> 24  
<211> 13  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer No. 2

<400> 24

ggccgacgtg gcc

13

<210> 25  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer No. 1

<220>  
<221> modified\_base  
<222> (13)..(18)  
<223> n = a, t, c or g

<400> 25

gacgtggcct gtnnnnnn

18

*B  
concl-*  
<210> 26  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer No. 2

<400> 26

ggccgacgtg gcctgt

16

<210> 27  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 27

ccctcatagt taagcgtaac g

21